Since Dylan encouraged me to follow through with some more up to date research information regarding SARMs, I had received several emails from corroborators involved in clinical research; After some digging around, I had come across an "under the radar" hint, that Pfizer has started applying for documentation to legitimately mass produce pharmaceutical grade SARMs for clinical purposes.
A lot of you probably heard rumours and studies involving human subjects, but until now, there were no substantial evidence that a pharmaceutical company is intending on filing a motion to start stage I clinical trials with intent to mass produce.
It seems that subsidiaries of a big pharma company, indirectly were involved in financing a recent study(1) in the Journal of Clinical Therapeutics earlier this past summer, pioneering a new compound which essentially is a SARMs that behaves in every way classically like the SARMs we use (2); Brand name has no been filed yet; This was revealed due to the commission of its mass production by MedKoo Biosciences(2).
So what does this research say?
Funny enough, this research is stating the same thing Dylan mentions in his videos about SARMs. The study(1) had undertaken task to dose, underdose, and superdose this SARM(2) in healthy human subject in a protocol of MAD (Multiple Ascending Doses) to potentially reveal any side effects.
In any medication, even the safest - there are side effects. They couldn't find any!; Not only that, to the keen observers this research has been scraped and had to be REDONE, since the study supervisors had a hard time reconciling no side effects, so they opened new groups with ethnic variety - still no side effects were documented(2)(3);
SARMs are scientifically proven to be safe in humans.
Why did they only test them on healthy subjects?
The way by which pharmaceuticals are developed, is via stages (i.e. stage I-IV); The first stage is to ascertain a fair level of safety, making sure the drug doesn't cause harm. This is done by initially looking into its effects on healthy subjects. (There are exception to this, such as drugs that are known to cause harm, but have a beneficial effect on sick subjects, such as some chemotherapeutic drugs)
If SARMs attain medicinal status, would they become illegal?
Not necessarily, and likely not. Even if the case may be a concern, it's years ahead. A compound being used for therapeutic applications doesn't mean it would be controlled. An example is over the counter anti histamines. Those could actually kill you, but they are not regulated. There are caveats, but I'll leave it at that, for now.
Why didn't they use existing ones?
First of all, if you wanna "make bank", you gotta come up with a new compound you can trademark and/or patent. It isn't that they passed on using the very ones we use because they are ineffective at all, or that theirs is more.
It is very possible (and is often done) that a new compound is made based on existing one, with small modifications that do not alter the biological activity or pharmacokinetic parameters at all - but that still is enough to claim a patent, since it's a new compound.
What is the difference between this SARM and the rest?
It's hard to say, since most of the research regarding the comparison between this SARM and the ones we used has no been filed yet, which is a known way to "control the market" and keep us in the dark. All the information I could find from other corroborators seems to point to the fact that the molecular appearance and function is virtually identical with MK-2866. It is hard to tell at the moment.
At any case, since the downstream cascade this compound elicits with respect to Androgen Receptor Modulation, the biological activity is identical to the SARMs we use, which implicated the same side effect profile; Or lack of it
Disclaimer
Bear in mind that additional research is always needed to sustain the status of lack of side effects, and I'm sure there are abstracts that have not even been published for financial purposes for 'beating the market'.
Thank you for reading.
References
(1)Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects; Journal of Clinical Therapeutics (2006)
Bhattacharya I1, Tarabar S2, Liang Y3, Pradhan V4, Owens J4, Oemar B4.
(2)MedKoo CAT#: 522576; CAS#: 1612755-71-1
(3)Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male; Subjects; ClinicalTrials.gov Identifier: NCT02070939
A lot of you probably heard rumours and studies involving human subjects, but until now, there were no substantial evidence that a pharmaceutical company is intending on filing a motion to start stage I clinical trials with intent to mass produce.
It seems that subsidiaries of a big pharma company, indirectly were involved in financing a recent study(1) in the Journal of Clinical Therapeutics earlier this past summer, pioneering a new compound which essentially is a SARMs that behaves in every way classically like the SARMs we use (2); Brand name has no been filed yet; This was revealed due to the commission of its mass production by MedKoo Biosciences(2).
So what does this research say?
Funny enough, this research is stating the same thing Dylan mentions in his videos about SARMs. The study(1) had undertaken task to dose, underdose, and superdose this SARM(2) in healthy human subject in a protocol of MAD (Multiple Ascending Doses) to potentially reveal any side effects.
In any medication, even the safest - there are side effects. They couldn't find any!; Not only that, to the keen observers this research has been scraped and had to be REDONE, since the study supervisors had a hard time reconciling no side effects, so they opened new groups with ethnic variety - still no side effects were documented(2)(3);
SARMs are scientifically proven to be safe in humans.
Why did they only test them on healthy subjects?
The way by which pharmaceuticals are developed, is via stages (i.e. stage I-IV); The first stage is to ascertain a fair level of safety, making sure the drug doesn't cause harm. This is done by initially looking into its effects on healthy subjects. (There are exception to this, such as drugs that are known to cause harm, but have a beneficial effect on sick subjects, such as some chemotherapeutic drugs)
If SARMs attain medicinal status, would they become illegal?
Not necessarily, and likely not. Even if the case may be a concern, it's years ahead. A compound being used for therapeutic applications doesn't mean it would be controlled. An example is over the counter anti histamines. Those could actually kill you, but they are not regulated. There are caveats, but I'll leave it at that, for now.
Why didn't they use existing ones?
First of all, if you wanna "make bank", you gotta come up with a new compound you can trademark and/or patent. It isn't that they passed on using the very ones we use because they are ineffective at all, or that theirs is more.
It is very possible (and is often done) that a new compound is made based on existing one, with small modifications that do not alter the biological activity or pharmacokinetic parameters at all - but that still is enough to claim a patent, since it's a new compound.
What is the difference between this SARM and the rest?
It's hard to say, since most of the research regarding the comparison between this SARM and the ones we used has no been filed yet, which is a known way to "control the market" and keep us in the dark. All the information I could find from other corroborators seems to point to the fact that the molecular appearance and function is virtually identical with MK-2866. It is hard to tell at the moment.
At any case, since the downstream cascade this compound elicits with respect to Androgen Receptor Modulation, the biological activity is identical to the SARMs we use, which implicated the same side effect profile; Or lack of it
Disclaimer
Bear in mind that additional research is always needed to sustain the status of lack of side effects, and I'm sure there are abstracts that have not even been published for financial purposes for 'beating the market'.
Thank you for reading.
References
(1)Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects; Journal of Clinical Therapeutics (2006)
Bhattacharya I1, Tarabar S2, Liang Y3, Pradhan V4, Owens J4, Oemar B4.
(2)MedKoo CAT#: 522576; CAS#: 1612755-71-1
(3)Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male; Subjects; ClinicalTrials.gov Identifier: NCT02070939
Last edited:
![[9oNe6]BillyD@kid](/forums/data/avatars/m/2/2076.jpg?1477587594){kind=avatar}
